演題抄録

一般演題(口演)

開催概要
開催回
第51回・2013年・京都
 

A prospective study of carboplatin and paclitaxel for advanced thymic carcinoma

演題番号 : O45-6

[筆頭演者]
Akira Ono:1 
[共同演者]
Fumihiko Hirai:2、Takeharu Yamanaka:3、Kenichi Taguchi:2、Koji Takeda:4、Haruko Daga:4、Junichi Shimizu:5、Junya Fukuoka:6、Kenichi Nishiyama:2、Takashi Seto:2、Yukito Ichinose:2、Kazuhiko Nakagawa:7、Yoichi Nakanishi:8

1:Shizuoka Cancer Center, Japan、2:National Kyushu Cancer Center, Japan、3:National Cancer Center Hospital East, Japan、4:Osaka City General Hospital, Japan、5:Aichi Cancer Center Hospital, Japan、6:Nagasaki Univ, Japan、7:Kinki Univ School of Medicine, Japan、8:Kyushu University Hospital, Japan

 

Background: Thymic carcinoma (TC) is a rare malignant tumor originated within the thymus gland and is associated with a poor prognosis, differing from thymoma which is the most common type of thymic malignant neoplasm. No results of clinical trials focusing on TC have been reported. This single-arm study evaluated carboplatin and paclitaxel (CbP) in previously untreated patients (pts) with advanced TC. Methods: Chemotherapy-naïve pts with Masaoka’s stage III to IVb, ECOG PS 0 to 1, and more than 20 years old were eligible. The study treatment consisted of carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 3 weeks for a maximum of 6 cycles. The primary endpoint was objective response rate (ORR) by extramural assessment. Secondary endpoints included overall survival (OS), progression-free survival (PFS), and safety. All pts were followed-up until 24 months (mo) after last enrollment. Results: From May 2008 to November 2010, 40 pts were enrolled from 21 centers. Of 39 evaluable for analysis, the median age was 62 years (range, 36-84); 23/16 males/females; 3/10/26 with Masaoka’s stage III/IVa/IVb; 9/11/19 with squamous cell carcinoma/poorly differentiated neuroendocrine carcinoma/other types. The median number of cycles was 6. There was 1/13 complete/partial responses with an ORR of 36% (95% CI, 21-53%; P = 0.031). The median PFS was 7.52 mo (6.18 - 12.32 mo) while OS did not reach the median value. The 1-year and 2-year survival rates were 85% (69-93%) and 71% (54-83%), respectively. Major adverse event was grade 3-4 neutropenia in 34 pts (87%). Two cases (5%) of grade 3 febrile neutropenia, neuropathy, and arthralgia were observed, respectively. There was no treatment-related death. Conclusions: CbP showed higher efficacy in advanced TC. Our results established that CbP, one of the standard treatments for non-small cell lung cancer, also serves as a key chemotherapy regimen for TC.

キーワード

臓器別:肺・縦隔・胸膜

手法別:化学療法

前へ戻る